The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development. These are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.
Background
The antibody trastuzumab and the tyrosine kinase inhibitor (TKI) lapatinib are approved by the FDA for the treatment of HER2-overexpressing (HER2+) breast cancer (MBC).
Trastuzumab binds to an epitope in the juxtamembrane region of the HER2 receptor. This binding induces uncoupling of ligand-independent HER2-HER3 heterodimers and inhibition of downstream signaling (1) as well as antibody-dependent, cell-mediated cytotoxicity (ADCC) (2) .
Several randomized adjuvant trials (NCCTG N9831, NSABP B-31, BCIRG 006, and HERA), have demonstrated that the addition of trastuzumab to standard chemotherapy reduces disease recurrence and the risk of death compared to chemotherapy alone in patients with surgicallyresected tumors (3) (4) (5) . In N-9831, a recent interim analysis showed that the benefit of concurrent trastuzumab and chemotherapy was more pronounced than that of chemotherapy followed by trastuzumab (6) . Based on these data, the addition of trastuzumab to adjuvant chemotherapy has become standard of care in women with HER2+ early breast cancer.
The trastuzumab adjuvant trials focused on high-risk, lymph node positive HER2+ tumors. Thus, there is limited to no data on small tumors (≤1 cm) with negative nodes and patient outcome. However, two recent studies found a significantly higher rate of recurrence among T1abN0 HER2+ compared to HER2-negative tumors regardless of ER status (7, 8) , suggesting adjuvant trastuzumab should be considered for these patients. However, the amount and type of chemotherapy to combine with the antibody in this setting is undetermined. Most of the adjuvant trials used one year of trastuzumab. One study delivered only 9 weeks of the antibody, whereas the HERA trial included an arm where it was given for 2 years. In the first Author Manuscript Published OnlineFirst on January 19, 2011; DOI: 10.1158/1078-0432. CCR-09-1947 study, patients in the trastuzumab arm exhibited fewer overall recurrences and improved overall survival compared to patients treated with chemotherapy alone (9) . Results in the 2-year arm in HERA are pending.
The dual EGFR/HER2 TKI lapatinib is active as first line monotherapy in patients with HER2+ MBC and in combination with capecitabine improves progression free survival compared to capecitabine alone (10, 11) . In the latter registration trial, fewer brain metastases occurred in women in the combination than in the monotherapy arm, suggesting a potential difference between lapatinib and trastuzumab as it applies to recurrences in the CNS (11) . In the registration study and in a second randomized trial of paclitaxel ± lapatinib in patients with MBC, the clinical benefit of lapatinib was limited to patients with HER2 overexpression by IHC and/or FISH (12) .
On the Horizon

HER2 testing, discordance, and conversion
The clinical activity of anti-HER2 agents has been limited to patients with HER2+ tumors as defined by intense membrane staining with HER2 antibodies in the majority of tumor cells (3+ by immunohistochemistry -IHC) or ≥2 copies of the HER2 gene determined by fluorescent in situ hybridization (FISH). In general, HER2 IHC and FISH correlate with each other (13) (14) (15) ).
FISH appears superior to IHC to reproducibly assess tumors for HER2 overexpression at outside/local laboratories for entry into clinical trials (16) . Intrinsic limitations of IHC are the variability in fixation methods and the impact of fixation of antigenicity of the HER2 protein.
Conversely, the more stable DNA, whose loci are measured by FISH, is less succeptible to tissue fixation. For these reasons, excess copies of the HER2 gene (so called HER2 positivity)
defined by FISH has gained ground as the standard to define odds of tumor dependence on HER2 and, therefore, response to HER2 antagonists (17) .
A reanalysis in a central laboratory of NSABP B-31 showed that 9.7% of patients enrolled on the basis of a test performed in a local laboratory had tumors that did not meet criteria for HER2 amplification by FISH or IHC (18). Notably, these patients also benefited from trastuzumab. This suggests that the local laboratory was correct and/or there is discordance in the levels of HER2 expression between micrometastases, whose clinical recurrence defines the endpoint of adjuvant trials, and the primary tumor, where the HER2 alteration was measured.
This possibility is further suggested by a study where 9/24 patients with breast cancer whose primary tumor was HER2-negative (HER2-) acquired HER2 amplification in their circulating tumor cells (CTCs) during cancer progression (19) . In another study, 10% of patients that recurred on adjuvant tamoxifen converted from HER2− to HER2+ in the relapsing tumor (20) . Of note, however, the HER2 status of CTCs has yet to be linked to clinical outcome. Based on data like these, the NSABP is initiating a phase III trial in which patients with 1+ or 2+ HER2 by IHC and no HER2 amplification by FISH will be randomized to adjuvant chemotherapy followed by one year of trastuzumab vs. placebo. 
Antibody-chemotherapy conjugates
Trastuzumab (T)-DM1 is an antibody-drug conjugate in which one molecule of trastuzumab is covalently bonded via a non-cleavable linker to three molecules of the microtubule polymerization inhibitor derivative of maytansine 1, DM1 (24) . T-DM1 binds to HER2 with similar affinity as trastuzumab. It is postulated that after binding, the T-DM1/HER2 complex is internalized followed by degradation in the lysosome, release of DM1, and subsequent cell lysis. Although used at lower doses and frequency than trastuzumab, T-DM1 retains the ability to inhibit signaling and engaging immune effectors that mediate ADCC and is active against lapatinib-resistant xenografts (25) heavily pretreated HER2+ MBC who had progressed after trastuzumab and lapatinib (26, 27) .
T-DM1 is being further evaluated in two large phase III randomized studies. The first trial compares T-DM1 vs. T-DM1 plus pertuzumab vs. the standard of trastuzumab plus a taxane in patients with HER2+ MBC previously untreated in the metastatic setting. The second trial compares T-DM1 vs. the standard of lapatinib and capecitabine in similar patients but who have previously received trastuzumab ( Table 1) .
Combination of anti-HER2 therapies and abrogation of drug resistance
Dual HER2 blockade. Many HER2-amplified breast cancers do not respond to or eventually escape trastuzumab, suggesting both de novo and acquired mechanisms of resistance. A possible mechanism of de novo resistance is expression of the HER2 receptor as a kinase-active 95-kDa cytosolic fragment that lacks the trastuzumab binding epitope (28) .
Analysis of a cohort of patients with HER2+ MBC treated with trastuzumab and chemotherapy showed a very low response rate in tumors with cytosolic p95 HER2 compared to those without (29) . Lapatinib has been shown to inhibit the catalytic activity of p95 HER2 . Therefore, patients with p95 HER2 -positive breast cancers treated with lapatinib alone or in combination with capecitabline exhibited a similar PFS and overall response rate compared to p95 HER2 -negative tumors (30) , suggesting a clinical setting where a HER2 TKI might be advantageous.
Like lapatinib, the HER2/EGFR dual TKI neratinib (31) has shown clinical activity in patients with HER2+ MBC who have progressed on trastuzumab. These data suggest that trastuzumab-resistant tumors continue to be dependent on the HER2 tyrosine kinase. However, the response to each single agent TKI tends to be short-lived (10, 11) . Further, these patients may still need trastuzumab beyond progression as suggested by a recent study where the combination of lapatinib and trastuzumab was superior to lapatinib alone at improving PFS, clinical response, and overall survival of patients with HER2+ MBC who had progressed on trastuzumab (32) . Taken together, these data imply that even in advanced stages, HER2+
breast cancers remain dependent on HER2 and that single-agent trastuzumab and lapatinib are not adequate to inhibit the HER2 network completely. They also imply that using combinations of HER2-targeted agents delivered early against HER2+ breast cancer is the rational approach to take. Along these lines, Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) is an ongoing large international adjuvant study comparing trastuzumab vs. lapapatinib vs. dual HER2 blockade using both drugs. The activity of trastuzumab beyond progression is not limited to combinations with TKIs as it has also been shown in a study where the combination of trastuzumab plus capecitabine was clearly superior to capecitabine alone (33) .
Research. 
Inhibition of HER3 and HER2/HER3 dimers. The HER2 co-receptor HER3, is the key adaptor that once dimerized with and phosphorylated by HER2 engages and activates the phosphatidylinositol-3 kinase (PI3K)/Akt pathway (1, 34, 35) . The association of HER2/HER3 dimers with PI3K is essential for the viability of HER2-dependent cells (36, 37) . Indeed, HER2+ breast cancer cells are particularly sensitive to apoptosis induced by PI3K inhibitors (38) (Fig. 1) .
Trastuzumab has been shown to block ligand-independent association between HER2 and HER3 whereas pertuzumab, an antibody that recognizes an epitope in heterodimerization domain II of HER2, blocks ligand-induced HER2-HER3 dimerization (43) . Recent data using CLIA-certified dimer assays suggest levels HER2-containing homo and heterodimers (with EGFR and HER3) can be measured in situ and are highly variable among HER2+ tumors (44, 45) . We hypothesize, for example, that a tumor with high levels of HER2/HER3 heterodimers would be relatively unresponsive to trastuzumab and thus may be a candidate for lapatinib or pertuzumab, each in combination with trastuzumab. These speculations and the question whether the addition of quantitative dimer assays to FISH and IHC for HER2 will refine the selection of the type of anti-HER2 therapy remain to be investigated.
In trastuzumab-resistant xenografts and in patients with HER2+ breast cancer that have progressed on trastuzumab, only the combination of pertuzumab and trastuzumab but not each antibody alone exhibited clinical activity (46, 47) . These data suggest that both HER2 antibodies might be required to completely inhibit HER2-HER3 dimerization in situ, potentially explaining their clinical activity in combination. To test this hypothesis, the phase III Cleopatra study (Table   1) is currently randomizing patients with HER2+ MBC to trastuzumab and docetaxel ± pertuzumab as first line therapy in the metastatic setting using PFS as a primary endpoint. Of note, in the recently reported NeoSphere trial in patients with HER2+ primary breast cancer (Table 1) , the path CR rate was 45.8% vs. 29% (p=0.01) in patients treated with neoadjuvant docetaxel/trastuzumab/pertuzumab vs. docetaxel/trastuzumab, respectively (48) . Currently, the HER3 monoclonal antibodies AMG-888 (49) and MM-121 (50) are completing phase I testing. We anticipate that like pertuzumab, they may also exert a synergistic effect in combination with trastuzumab or lapatinib in patients with HER2+ MBC.
PI3K and drug resistance. Amplification of PI3K signaling as a result co-expression of
PIK3CA-activating mutations or loss of the lipid phosphatase PTEN in HER2+ breast cancer cells and primary tumors is associated with a lower response to trastuzumab and lapatinib (51) (52) (53) (54) (55) . Several PI3K pathway antagonists are in clinical development and are the subject of recent reviews (56, 57) . In preclinical studies, the addition of some of these inhibitors to trastuzumab or lapatinib has inhibited growth of HER2+ tumors resistant to anti-HER2 therapy (53, 54) . Patients were treated with the TOR inhibitor everolimus, paclitaxel, and trastuzumab, exhibiting an impressive partial response rate of 19% and an overall clinical benefit rate of 81% (58) .
Neoadjuvant therapy as a platform for clinical research. Trastuzumab has been
administered with chemotherapy in the neoadjuvant setting with rates of pathologic complete response (path CR) as high as 65% (22, (59) (60) (61) (62) . Achievement of path CR after neoadjuvant chemotherapy has been widely associated with improved long term outcome.
Although not yet clear, recent data suggest similar conclusions may eventually also apply to patients treated with neoadjuvant anti-HER2 therapy. The neoadjuvant herceptin (NOAH) trial tested the efficacy of chemotherapy ± trastuzumab in patients with HER2+ locally advanced or inflammatory breast cancer. Path CR rate was 38% vs. 19% in the trastuzumab vs. the control group. There was a 71% vs. 56% three-year event-free survival in the trastuzumab vs. control arms in all subgroups tested. Overall survival was not different between both arms but this finding is qualified by the fact that a significant proportion of patients 'crossed-over' to adjuvant trastuzumab (62) .
Nonetheless, NOAH is the first trial in patients with HER2+ tumors where path CR mirrors longer term event-free survival, suggesting use of the neoadjuvant therapy space as a platform for clinical investigation which we will discuss below.
Neo-ALTTO is a 450 patient study where HER2+ tumors >2 cm were randomized to trastuzumab, lapatinib, or the combination for 6 weeks, time at which paclitaxel is added to each of the arms for additional 12 weeks. After surgery, all 3 arms will receive adjuvant chemotherapy with FEC followed by the respective HER2 inhibitor either alone or in combination for 34 weeks.
About half of the patients enrolled had ER+ tumors. There was increased but manageable toxicity in the lapatinib arms (diarrhea, transaminitis). Path CR, defined as no invasive cancer in 
the breast or only DCIS in the breast specimen, was significantly higher in the combination arm (51.3%) vs. 29.5% and 24.7% in the trastuzumab and lapatinib arms, respectively. In all 3 arms, the path CR rate was lower in the ER+ vs. the ER-tumors (63) . Whether path CR correlates with disease-free and overall survival is pending further follow-up.
Other combinations. The data summarized above suggest that in addition to the combination of trastuzumab and lapatinib, many other rational combinations are or will soon be available for clinical testing. Examples of two-drug combinations that will inhibit the HER2 network and its output to PI3K/Akt more comprehensively are: trastuzumab plus pertuzumab, trastuzumab or lapatinib plus a HER3 neutralizing antibody, trastuzumab or lapatinib plus a PI3K or an AKT inhibitor, a PI3K pathway inhibitor plus a HER3 antibody, T-DM1 plus pertuzumab or a PI3K inhibitor, a combination of HER2 and IGF-IR pathway antagonists, among others. Some of these are shown in Table 1 . We speculate many of these or all will be well tolerated and effective against HER2+ MBC but that gain will likely be only incremental.
With the establishment of current anti-HER2 agents as adjuvant therapy for HER2+ early disease and the increasing limitation in patient resources, it will be difficult to move these combinations to the adjuvant setting to test their true anti-(micro)metastatic potency using survival as an endpoint.
However, the increasing use of pre-operative therapy should provide a clinical research platform where these combinations can be compared and triaged using path CR as a clinical endpoint predictive of long term outcome. Another benefit of a pre-operative platform is that residual tumor tissue is available at the time of surgery. These 'drug resistant' residual cancers may well reflect the molecular profile of drug-resistant micrometastases and can be interrogated with open ended molecular approaches to identify biomarkers and/or effectors of resistance to anti-HER2 therapies. It would not be too surprising if the clinical activity of these combinations turns out to be equivalent. However, toxicity and cost may turn out to be important differentiating factors. If so, just like options for endocrine therapy in ER+ breast cancer, this scenario would provide a plethora of treatment choices for patients with HER2-overexpressing breast cancer who in the end will be the winners. Research. 
